BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

BACKGROUND: Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted therapies for PeM exist. Some immune checkpoint inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Raunak, Nabavi, Noushin, Lin, Yen-Yi, Mo, Fan, Anderson, Shawn, Volik, Stanislav, Adomat, Hans H., Lin, Dong, Xue, Hui, Dong, Xin, Shukin, Robert, Bell, Robert H., McConeghy, Brian, Haegert, Anne, Brahmbhatt, Sonal, Li, Estelle, Oo, Htoo Zarni, Hurtado-Coll, Antonio, Fazli, Ladan, Zhou, Joshua, McConnell, Yarrow, McCart, Andrea, Lowy, Andrew, Morin, Gregg B., Chen, Tianhui, Daugaard, Mads, Sahinalp, S. Cenk, Hach, Faraz, Le Bihan, Stephane, Gleave, Martin E., Wang, Yuzhuo, Churg, Andrew, Collins, Colin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378747/
https://www.ncbi.nlm.nih.gov/pubmed/30777124
http://dx.doi.org/10.1186/s13073-019-0620-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378747/
https://www.ncbi.nlm.nih.gov/pubmed/30777124
http://dx.doi.org/10.1186/s13073-019-0620-3

Ejemplares similares